NCT03150056 - Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

July 31, 2020

Study Completion Date

June 22, 2021

Conditions

Solid Tumours

Interventions

DRUG

GSK525762

GSK525762 will be administered.

DRUG

Abiraterone

Abiraterone will be administered.

DRUG

Enzalutamide

Enzalutamide will be administered.

DRUG

Prednisone

Prednisone will be administered as a concomitant medication in combination with abiraterone

Trial Locations (20)

2050

GSK Investigational Site, Sydney

3000

GSK Investigational Site, Melbourne

3168

GSK Investigational Site, Clayton

8036

GSK Investigational Site, Barcelona

10016

GSK Investigational Site, New York

19104

GSK Investigational Site, Philadelphia

21204

GSK Investigational Site, Towson

21287

GSK Investigational Site, Baltimore

28034

GSK Investigational Site, Madrid

39008

GSK Investigational Site, Santander

48201

GSK Investigational Site, Detroit

53792

GSK Investigational Site, Madison

63110

GSK Investigational Site, St Louis

90033

GSK Investigational Site, Los Angeles

02215

GSK Investigational Site, Boston

08035

GSK Investigational Site, Barcelona

3075EA

GSK Investigational Site, Málaga

08208

GSK Investigational Site, Sabadell (Barcelona)

SM2 5NG

GSK Investigational Site, Sutton

G12 OYN

GSK Investigational Site, Glasgow